Patents by Inventor Vasileios Askoxylakis

Vasileios Askoxylakis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS
    Publication number: 20240082218
    Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 14, 2024
    Inventors: Vasileios ASKOXYLAKIS, Saskia Maria BRACHMANN, Simona COTESTA, Xiaoming CUI, Jeffrey ENGELMAN, Anna FARAGO, Marc GERSPACHER, Diana GRAUS PORTA, Catherine LEBLANC, Edwige Liliane Jeanne LORTHIOIS, Bo LIU, Rainer MACHAUER, Robert MAH, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea Helga Emmi VAUPEL, Nicolas WARIN, Andreas WEISS, Rainer WILCKEN, Padmaja YERRAMILLI-RAO
  • CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER
    Publication number: 20230181756
    Abstract: This application discloses compositions and methods of treating follicular lymphoma using CCR7 antibody drug conjugates. Also disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to said subject an antibody drug conjugate, wherein the cancer expresses CCR7, wherein the antibody drug conjugate is administered to said subject at about 0.1 mg/kg to about 10 mg/kg.
    Type: Application
    Filed: April 11, 2021
    Publication date: June 15, 2023
    Inventors: Vasileios ASKOXYLAKIS, Michelle COULSON, Anhthu DANG, Yuyan DUAN, Jessica MAKOFSKE, Sabine ROTTMANN, Xiaoli WANG
  • Treatment of breast cancer brain metastases
    Patent number: 10689459
    Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) a Her3 antagonist, for simultaneous, separate or sequential administration for the treatment of breast cancer brain metastases; a method of treating a subject having a breast cancer brain metastases comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of breast cancer brain metastases; and a commercial package comprising such combination.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: June 23, 2020
    Assignees: Novartis AG, The General Hospital Corporation
    Inventors: Qing Sheng, Rakesh K. Jain, Vasileios Askoxylakis, Gino B. Ferraro, Dai Fukumura, David P. Kodack
  • Hydrophobic modified peptides for liver specific diagnosis
    Patent number: 10363323
    Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The present invention furthermore relates to the diagnostic use of the inventive hydrophobic modified peptides as well as to a method for the diagnosis of liver diseases or disorders.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: July 30, 2019
    Assignee: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn, Thomas Müller, Vasileios Askoxylakis
  • TREATMENT OF BREAST CANCER BRAIN METASTASES
    Publication number: 20190211110
    Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) a Her3 antagonist, for simultaneous, separate or sequential administration for the treatment of breast cancer brain metastases; a method of treating a subject having a breast cancer brain metastases comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of breast cancer brain metastases; and a commercial package comprising such combination.
    Type: Application
    Filed: December 10, 2015
    Publication date: July 11, 2019
    Inventors: Qing SHENG, Rakesh K. JAIN, Vasileios ASKOXYLAKIS, Gino B. FERRARO, Dai FUKUMURA, David P. KODACK
  • HYDROPHOBIC MODIFIED PEPTIDES FOR LIVER SPECIFIC DIAGNOSIS
    Publication number: 20140356284
    Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The present invention furthermore relates to the diagnostic use of the inventive hydrophobic modified peptides as well as to a method for the diagnosis of liver diseases or disorders.
    Type: Application
    Filed: February 10, 2012
    Publication date: December 4, 2014
    Inventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn, Thomas Müller, Vasileios Askoxylakis